Atreca Inc (FRA:0C1)
€ 0.0435 -0.0715 (-62.17%) Market Cap: 2.93 Mil Enterprise Value: -15.66 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Atreca Inc at Stifel Healthcare Conference Transcript

Nov 15, 2022 / 01:00PM GMT
Release Date Price: €1.38 (-2.13%)
Unidentified Analyst

(technical difficulty) of the in-person Stifel Healthcare Conference. Glad to have with us here, to start things off this morning, Atreca. We have the Chief Executive Officer, John Orwin. We have the Chief Strategy Officer, Tito Serafini; and the new Chief Scientific Officer, Stephen Gould.

I don't know, John, if you want to make any opening comments at all before we get into Q&A. Or do you want to --?

John Orwin
Atreca, Inc. - President and CEO

Sure. I mean, maybe I'll just -- for people who aren't familiar with the company -- just comment briefly on who we are and what we do. We discover antibody target pairs by interrogating human immune responses, specifically looking at a subset of B cells that emerge in the presence of infectious disease or -- which is kind of where the company had its roots -- and in cancer patients. And by sequencing those plasmablasts, we identify antibodies that are binding to novel tumor antigens that are shared tumor antigens. And this platform is something that we've been investing in now for, I guess, 10

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot